Mammography Screening and Breast Cancer Mortality in Sweden

Autier, Philippe; Koechlin, Alice; Smans, M.; Vatten, Lars J.; Boniol, Mathieu

doi:10.1093/jnci/djs272

Cited by 48 publications

(50 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These trends are in accordance with the experiences reported in the UK, the Netherlands, Sweden, and Norway, though not always on a comparable scale [9,10,11,12]. Within the next few years, it can be expected that the incidence will further decrease in response to the decreasing number of first-round participants.…”

Section: Discussionsupporting

confidence: 89%

Implementation of the German Mammography Screening Program (German MSP) and First Results for Initial Examinations, 2005-2009

Malek¹,

Kääb-Sanyal²

2016

Breast Care

View full text Add to dashboard Cite

Background: The German Mammography Screening Program (German MSP) is population-based and intended for women aged 50-69 years (approximately 10.5 million). The program started in 2005 and was implemented within 5 years. This article describes the implementation, structure, and screening process, and presents the results of initial examinations for the prevalence phase. Methods: Data were collected annually from invitation centers (invitation, attendance), screening units (performance, outcomes), and cancer registries (incidence). Results: In 2009, 92% of all annually eligible women were invited; 50% of the annually eligible population participated. The total cancer detection rate in the period of 2005-2009 was 8.1/1,000; the corresponding recall rate was 5.9%. 19.6% of detected cancers were ductal carcinoma in situ; 76.7% of invasive cancers were ≤ 20 mm in size, 30.2% were ≤ 10 mm, and 75.3% were node-negative. During the implementation period, incidence increased by 37 and 56% in the old and new federal states, respectively. Incidence rates decreased following the prevalence phase. Conclusion: The German MSP was successfully implemented. The results of the prevalence phase meet the target values of the European guidelines. Proper functioning of the program is also verified by its effects on breast cancer incidence. To draw reliable conclusions regarding the long-term effects of the program, results from the routine screening rounds have to be awaited.

show abstract

Section: Discussionsupporting

confidence: 89%

Implementation of the German Mammography Screening Program (German MSP) and First Results for Initial Examinations, 2005-2009

Malek¹,

Kääb-Sanyal²

2016

Breast Care

View full text Add to dashboard Cite

show abstract

“…This observation further casts doubt on some negative results of analyses of published mortality rates that include deaths from cancers diagnosed outside the screening period-ie, cancers that could not have been aff ected by the intervention. 15,16 In women who attended screening in response to the fi rst invitation compared to the control group, the rate ratio for breast cancer mortality was 0·83 (95% CI 0·65-1·06) overall when restricted to cancers diagnosed in the intervention phase. Previous estimates of the extent of screening in the control group suggest that screening was limited, with only 4% of a sample of 2000 women reporting a mammogram other than for symptomatic reasons within the previous 3 years.…”

Section: Discussionmentioning

confidence: 99%

Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial

Moss

Wale

Smith

et al. 2015

The Lancet Oncology

179

108

View full text Add to dashboard Cite

SummaryBackground Age-specifi c eff ects of mammographic screening, and the timing of such eff ects, are a matter of debate. The results of the UK Age trial, which compared the eff ect of invitation to annual mammographic screening from age 40 years with commencement of screening at age 50 years on breast cancer mortality, have been reported at 10 years of follow-up and showed no signifi cant diff erence in mortality between the trial groups. Here, we report the results of the UK Age trial after 17 years of follow-up.

show abstract

“…Although this method generally can accommodate all kinds of outcomes and exposures, its use to date has been limited almost exclusively to time trend analyses (e.g., [4,29,37]). …”

Section: Threshold Estimation By Segmented Regressionmentioning

confidence: 99%

Calcium intake and bone mineral density as an example of non-linearity and threshold analysis

Breitling

2015

Osteoporos Int

View full text Add to dashboard Cite

Knowing about the possibilities and limitations of non-linear dose-response approaches should encourage researchers to consider these methods more frequently in studies on bone health and disease. The example analysis suggested bone mineral density to reach a plateau slightly below current calcium intake recommendations, with fairly pronounced differences of the dose-response shape by sex and menopausal status.

show abstract

Mammography Screening and Breast Cancer Mortality in Sweden

Cited by 48 publications

References 39 publications

Implementation of the German Mammography Screening Program (German MSP) and First Results for Initial Examinations, 2005-2009

Implementation of the German Mammography Screening Program (German MSP) and First Results for Initial Examinations, 2005-2009

Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial

Calcium intake and bone mineral density as an example of non-linearity and threshold analysis

Contact Info

Product

Resources

About